|
MechanismSerine protease inhibitors |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.JP |
First Approval Date31 Mar 1989 |
[Translation] Pharmacokinetic study of nafamostat mesylate for injection in humans
研究健康志愿者单次(10 mg、20 mg、40 mg)和多次(20 mg)给药的药代动力学特征,了解不同剂量甲磺酸萘莫司他在人体内动态变化的规律及其剂量相关性,以及多次连续给药体内蓄积情况,为制定合理临床给药方案提供依据。
[Translation] To study the pharmacokinetic characteristics of single (10 mg, 20 mg, 40 mg) and multiple (20 mg) administrations in healthy volunteers, and to understand the dynamic changes of nafamostat mesylate at different doses in the human body. The dose correlation and the accumulation in vivo after multiple consecutive administrations provide a basis for formulating a rational clinical dosing regimen.
以肝素钠注射液为对照评价注射用甲磺酸萘莫司他用于血液透析抗凝有效性和安全性的多中心、随机、盲法试验
[Translation] A multicenter, randomized, blinded trial to evaluate the efficacy and safety of nafamostat mesylate for hemodialysis anticoagulation with heparin sodium injection as a control
以肝素钠注射液为对照,评价注射用甲磺酸萘莫司他用于血液透析抗凝的有效性和安全性。
[Translation] Taking heparin sodium injection as a control, the efficacy and safety of nafamostat mesylate for injection in hemodialysis anticoagulation were evaluated.
100 Clinical Results associated with Lanzhou Jinglong Pharmaceutical Technology Co Ltd
0 Patents (Medical) associated with Lanzhou Jinglong Pharmaceutical Technology Co Ltd
100 Deals associated with Lanzhou Jinglong Pharmaceutical Technology Co Ltd
100 Translational Medicine associated with Lanzhou Jinglong Pharmaceutical Technology Co Ltd